[Treatment of urinary tract infections with amikacin (BB-K8) (author's transl)].
D000208:Acute Disease; D000328:Adult; D000368:Aged; D000613:Aminobutyrates / Q000009:adverse effects / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use / Q000652:urine; D002648:Child; D002675:Child, Preschool; D002908:Chronic Disease; D003556:Cystitis / Q000188:drug therapy; D004352:Drug Resistance, Microbial; D004755:Enterobacteriaceae / Q000187:drug effects; D004926:Escherichia coli / Q000187:drug effects; D005260:Female; D006069:Gonorrhea / Q000188:drug therapy; D006801:Humans; D007612:Kanamycin / Q000009:adverse effects / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use* / Q000652:urine; D008297:Male; D008875:Middle Aged; D011511:Proteus / Q000187:drug effects; D011549:Pseudomonas / Q000187:drug effects; D011704:Pyelonephritis / Q000188:drug therapy; D013210:Staphylococcus / Q000187:drug effects; D014552:Urinary Tract Infections / Q000188:drug therapy*
D000613:Aminobutyrates; D007612:Kanamycin